Latest & greatest articles for sumatriptan

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on sumatriptan or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on sumatriptan and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for sumatriptan

21. Costs and outcomes of early versus delayed migraine treatment with sumatriptan

Costs and outcomes of early versus delayed migraine treatment with sumatriptan Costs and outcomes of early versus delayed migraine treatment with sumatriptan Costs and outcomes of early versus delayed migraine treatment with sumatriptan Halpern M T, Lipton R B, Cady R K, Kwong W J, Marlo K O, Batenhorst A S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of early sumatriptan treatment for mild migraine versus delayed sumatriptan treatment for moderate to severe migraine. Doses of 50 mg or 100 mg were considered for both treatments. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised a hypothetical cohort of patients experiencing mild migraine

2002 NHS Economic Evaluation Database.

22. Sumatriptan: economic evidence for its use in the treatment of migraine, the Canadian comparative economic analysis

Sumatriptan: economic evidence for its use in the treatment of migraine, the Canadian comparative economic analysis Sumatriptan: economic evidence for its use in the treatment of migraine, the Canadian comparative economic analysis Sumatriptan: economic evidence for its use in the treatment of migraine, the Canadian comparative economic analysis Caro G, Getsios D, Caro J J, Raggio G, Burrows M, Black L Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of sumatriptan in the treatment of patients with migraine. Six alternative strategies with sumatriptan were analysed: subcutaneous sumatriptan, 6mg; oral sumatriptan, 100 mg; oral sumatriptan, 50 mg; sumatriptan nasal spray, 10 mg; sumatriptan nasal spray, 20 mg; sumatriptan

2001 NHS Economic Evaluation Database.

23. Economic implications of early treatment of migraine with sumatriptan tablets

Economic implications of early treatment of migraine with sumatriptan tablets Economic implications of early treatment of migraine with sumatriptan tablets Economic implications of early treatment of migraine with sumatriptan tablets Cady R K, Sheftell F, Lipton R B, Kwong W J, O'Quinn S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The early treatment of migraine with sumatriptan was studied. Two dosages, 50 and 100 mg, were considered. These were administered when the pain was mild. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised a hypothetical cohort of 1,000 patients suffering from mild migraine. All patients had a diagnosis of migraine

2001 NHS Economic Evaluation Database.

24. Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine

Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine Lofland J H, Kim S S, Batenhorst A S, Johnson N E, Chatterton M L, Cady R K, Kaniecki R, Nash D B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Sumatriptan therapy was compared with nontriptan medications in the treatment of acute migraine. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population To be included in the study, the patients had to meet three criteria. First, to have a doctor's diagnosis of migraine. Second, to have received

2001 NHS Economic Evaluation Database.

25. Cost-benefit analysis of sumatriptan tablets versus usual therapy for treatment of migraine

Cost-benefit analysis of sumatriptan tablets versus usual therapy for treatment of migraine Cost-benefit analysis of sumatriptan tablets versus usual therapy for treatment of migraine Cost-benefit analysis of sumatriptan tablets versus usual therapy for treatment of migraine Biddle A K, Shih Y C, Kwong W J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of sumatriptan tablets (50 mg) for the treatment of migraine. Type of intervention Treatment. Economic study type Cost-benefit analysis. Study population The study population comprised patients suffering from migraine. The specific inclusion and exclusion criteria were not reported. Setting The setting was primary care. The economic study was conducted in the USA

2000 NHS Economic Evaluation Database.

26. Use of decision analysis in modeling the cost-effectiveness of oral vs SC sumatriptan

Use of decision analysis in modeling the cost-effectiveness of oral vs SC sumatriptan Use of decision analysis in modeling the cost-effectiveness of oral vs SC sumatriptan Use of decision analysis in modeling the cost-effectiveness of oral vs SC sumatriptan Joish V N, Armstrong E P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of oral versus subcutaneous (SC) sumatriptan, a serotonin agonist, in the treatment of migraine headache. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised a hypothetical cohort of patients aged 18 to 65 years with clinically diagnosed migraine. Setting The setting was unclear. The economic study was conducted

2000 NHS Economic Evaluation Database.

27. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat

Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat Tfelt-Hansen P Authors (...) ' objectives To assess the efficacy, speed of onset and adverse events of sumatriptan given using various routes of administration for migraine treatment. Searching The author searched MEDLINE (over the entire date range, performed in April 1997), using the terms 'migraine', 'sumatriptan', and 'clinical trials'. Printouts from the database on clinical trials on sumatriptan were obtained from Glaxo Wellcome Denmark. The journals 'Archives of Neurology', 'Neurology', 'Headache' and 'Cepalalgia' from 1990

1998 DARE.

28. Subcutaneous sumatriptan compared with usual acute treatments for migraine: clinical and pharmacoeconomic evaluation

Subcutaneous sumatriptan compared with usual acute treatments for migraine: clinical and pharmacoeconomic evaluation Subcutaneous sumatriptan compared with usual acute treatments for migraine: clinical and pharmacoeconomic evaluation Subcutaneous sumatriptan compared with usual acute treatments for migraine: clinical and pharmacoeconomic evaluation Laloux P, Vakaet A, Monseu G, Jacquy J, Bourgeois P, van der Linden C Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Subcutaneous sumatriptan 6mg in acute treatments for migraine. Subcutaneous sumatriptan was chosen because of its high biodisponibility and its proven efficacy in relieving pain more quickly than the oral form. Type of intervention Treatment. Economic study type Cost

1998 NHS Economic Evaluation Database.

29. Economic evaluation of oral sumatriptan compared with oral caffeine/ergotamine for migraine

Economic evaluation of oral sumatriptan compared with oral caffeine/ergotamine for migraine Economic evaluation of oral sumatriptan compared with oral caffeine/ergotamine for migraine Economic evaluation of oral sumatriptan compared with oral caffeine/ergotamine for migraine Evans K W, Boan J A, Evans J L, Shuaib A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Oral drug therapy for migraine headache, specifically sumatriptan and caffeine/ergotamine. Type of intervention Treatment. Economic study type Cost-effectiveness, cost-utility and cost-benefit analyses were performed. Study population The study population was stated to be individuals aged 18-65 years, with moderate to severe migraine. Pregnant women

1997 NHS Economic Evaluation Database.

30. An economic analysis of sumatriptan for acute migraine - summary

An economic analysis of sumatriptan for acute migraine - summary An economic analysis of sumatriptan for acute migraine An economic analysis of sumatriptan for acute migraine Ilerisch L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ilerisch L. An economic analysis of sumatriptan for acute migraine. Ottawa: Canadian Coordinating Office (...) for Health Technology Assessment (CCOHTA). 1997 Authors' objectives To evaluate the cost and efficacy of sumitriptan from both the societal and Ministry of Health perspectives using models for cost-effectiveness, cost-utility, and cost benefit analyses. Project page URL Link to NHS EED abstract Indexing Status Subject indexing assigned by CRD MeSH Migraine Disorders /drug therapy; Sumatriptan /therapeutic use Language Published English, French Country of organisation Canada Address for correspondence 600

1997 Health Technology Assessment (HTA) Database.

31. Cost-effectiveness of sumatriptan in a managed care population

Cost-effectiveness of sumatriptan in a managed care population Cost-effectiveness of sumatriptan in a managed care population Cost-effectiveness of sumatriptan in a managed care population Legg R F, Sclar D A, Nemec N L, Tarnai J, Mackowiak J I Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology Sumatriptan injectable in the treatment of migraine headache. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Adult patients (older than 18 years) with migraine headache who have used sumatriptan at least once. Setting Community. The economic study was performed in Washington, the USA. Dates to which data relate The effectiveness and resource use data were related to the period between

1997 NHS Economic Evaluation Database.

32. Cost benefit of sumatriptan to an employer

Cost benefit of sumatriptan to an employer Cost benefit of sumatriptan to an employer Cost benefit of sumatriptan to an employer Legg R F, Sclar D A, Nemec N L, Tarnai J, Mackowiak J I Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health (...) technology Sumatriptan use in treating acute migraine Type of intervention Treatment. Economic study type Cost-benefit analysis. Study population Sumatriptan-using enrolees of an Independent Practice Association health maintenance organisation (IPA-HMO). Setting The setting was the community. Dates to which data relate Productivity costs were based on average wage rates by occupational class for the US population in 1993. Sumatriptan users were identified in 1994. Telephone interviews were conducted

1997 NHS Economic Evaluation Database.

33. Work productivity and resource consumption among migraineurs under current treatment and during treatment with sumatriptan: an economic evaluation of acute treatment in moderate to severe migraineurs

Work productivity and resource consumption among migraineurs under current treatment and during treatment with sumatriptan: an economic evaluation of acute treatment in moderate to severe migraineurs Work productivity and resource consumption among migraineurs under current treatment and during treatment with sumatriptan: an economic evaluation of acute treatment in moderate to severe migraineurs Work productivity and resource consumption among migraineurs under current treatment and during (...) treatment with sumatriptan: an economic evaluation of acute treatment in moderate to severe migraineurs Larbig W, Bruggenjurgen B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Sumatriptan in moderate to severe migraineurs. Up to two

1997 NHS Economic Evaluation Database.

34. An economic analysis of sumatriptan for acute migraine

An economic analysis of sumatriptan for acute migraine An economic analysis of sumatriptan for acute migraine An economic analysis of sumatriptan for acute migraine Ilersich L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology (...) Oral and subcutaneous sumatriptan for aborting or relieving migraine attacks. Type of intervention Treatment. Economic study type Cost-effectiveness analysis, cost-utility analysis and cost-benefit analysis. Study population Patients presenting with moderate or severe migraine events. Setting Primary care and hospital. The economic study was carried out in Canada. Dates to which data relate The effectiveness data were obtained from a previously completed meta-analysis published in 1996. No specific

1997 NHS Economic Evaluation Database.

35. Meta-analytic review of the effect of subcutaneous sumatriptan in migraine headache

Meta-analytic review of the effect of subcutaneous sumatriptan in migraine headache Meta-analytic review of the effect of subcutaneous sumatriptan in migraine headache Meta-analytic review of the effect of subcutaneous sumatriptan in migraine headache Harrison D L, Slack M K Authors' objectives To present a meta-analytic review of the effects of sumatriptan (6 mg) given subcutaneusly (sc), compared with placebo, in the acute treatment of migraine headache as reported by the proportion (...) of patients improved and pain free, and those needing a second dose, rescue medication or experiencing adverse effects. Searching MEDLINE was searched, although thw years were not stated and the keywords were not provided. In addition, all volumes of International Pharmaceutical Abstracts since 1990 were searched manually. The manufacturers of sumatriptan (Glaxo Inc.) were contacted, and the reference lists of identified studies and published reviews were examined. Study selection Study designs

1996 DARE.

36. Impact of sumatriptan on clinic utilization and costs of care in migraineurs

Impact of sumatriptan on clinic utilization and costs of care in migraineurs Impact of sumatriptan on clinic utilization and costs of care in migraineurs Impact of sumatriptan on clinic utilization and costs of care in migraineurs Litaker D G, Solomon G D, Genzen J R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. Health technology Sumatriptan in the treatment of migraine. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients regularly attending a migraine headache clinic, with migraine headaches meeting International Headache Society criteria, between March and December 1993. Clients were 85% female; 95% Caucasian; mean age = 43.35 years (+ Setting The practice setting

1996 NHS Economic Evaluation Database.

37. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. (PubMed)

The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Aspirin is commonly used to treat migraine attacks, although sumatriptan, a much more expensive treatment, is also effective. We compared a combination of lysine acetylsalicylate (equivalent to 900 mg aspirin) and 10 mg metoclopramide (LAS+MTC) with oral sumatriptan (100 mg) and placebo in 421 patients with migraine. LAS+MTC was as effective as sumatriptan with a decrease (...) of headache from severe or moderate to mild or none of 57% and 53%, respectively, for the first migraine attack treated. Both treatments were better than placebo (success rate 24%, p < 0.0001). LAS+MTC was significantly more effective in the treatment of nausea than sumatriptan (p < 0.0001) and was better tolerated (adverse events in 18% and 28%, respectively, p < 0.05). LAS+MTC is as effective as sumatriptan in the treatment of migraine attacks. It is also much cheaper.

1995 Lancet

38. Is chest pain after sumatriptan oesophageal in origin? (PubMed)

Is chest pain after sumatriptan oesophageal in origin? 3-5% of patients taking the 5HT1D agonist sumatriptan for migraine have chest discomfort, suggesting a cardiac origin. We have investigated an alternative explanation of an oesophageal cause in 24 volunteers after the subcutaneous administration of a supratherapeutic dose of sumatriptan (16 mg) or placebo in a randomised, double-blind crossover study. Sumatriptan did not alter the electrocardiogram but increased the amplitude (p < 0.001 (...) ) and duration (p < 0.001) of oesophageal contractions without affecting velocity of propagation. Clinically abnormal motility was also increased (p = 0.001), and was more common in the 5 subjects with chest pain after sumatriptan. The effect of sumatriptan on oesophageal function provides an alternative explanation for the chest symptoms.

1994 Lancet

39. Oral sumatriptan in acute migraine. (PubMed)

Oral sumatriptan in acute migraine. The efficacy in acute migraine of oral sumatriptan was assessed in a double-blind, randomised, placebo-controlled, crossover study of 61 patients (mean age 39 [SD 10] years). 41 completed treatment of four attacks, two with sumatriptan 100 mg and two with placebo. The response rate (reduction in headache from moderate or severe to mild or absent at 2 h) was 51% (45/89) with sumatriptan and 10% (9/93) with placebo (p less than 0.01); rescue medication (...) was needed at 2 h in 41% and 88%, respectively. Of 28 patients headache-free at 24 h, 11 (39%) had recurrent headache within 24 h. There were no substantial side-effects. Thus, sumatriptan is an effective well-tolerated treatment for acute migraine attacks.

1991 Lancet

40. Treatment of acute migraine with subcutaneous sumatriptan. (PubMed)

Treatment of acute migraine with subcutaneous sumatriptan. Sumatriptan succinate, a 5-HT1D receptor agonist, constricts human cranial arteries. Two parallel-group trials for treatment of acute migraines were conducted in the United States. Adult patients were randomized and given either 6 mg of sumatriptan succinate subcutaneously (n = 734) or placebo (n = 370). At 1 hour, sumatriptan was significantly more effective than placebo in reducing moderate or severe headache pain to mild or no pain (...) (70% vs 22%), in completely relieving headaches (49% vs 9%), and in improving clinical disability (76% vs 34%). Sumatriptan also reduced nausea and photophobia significantly better than placebo. Patients with residual migraines received another injection; those who had originally received sumatriptan received either a second active injection (n = 187) or placebo (n = 178), while those who had received placebo received a second placebo injection (n = 335). Statistical evidence for benefit of second

1991 JAMA